FIELD: medicine.
SUBSTANCE: invention relates to new compounds of 6-heterocyclyl-4-morpholine-4-ilpyridine-2-one of the formula (I), pharmaceutical compositions, use of such compounds in the treatment of diseases, including cancer, diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders and viral infections.
EFFECT: obtaining new compounds for the treatment of diseases.
28 cl, 2 tbl, 51 ex
Title | Year | Author | Number |
---|---|---|---|
6-ARYL-4-MORPHOLINE-1-YL PYRIDONES SUITABLE FOR TREATMENT OF CANCER OR DIABETES | 2017 |
|
RU2754664C2 |
MORPHOLINYL PYRIDONES | 2018 |
|
RU2803158C2 |
PYRIDYLPYRIDONES | 2018 |
|
RU2805334C2 |
PYRIDINAMINPYRIDONES AND PYRIMIDINAMINPYRIDONES | 2018 |
|
RU2804638C2 |
AZAINDOLYL PYRIDONE AND DIAZAINDOLYL PYRIDONE | 2018 |
|
RU2788659C2 |
PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS FOR APPLICATION | 2012 |
|
RU2638552C2 |
COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2597364C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2589878C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
Authors
Dates
2021-12-24—Published
2017-02-17—Filed